The Legacy of Acceleron Pharma: A Landmark Acquisition by Merck

Investors searching for Acceleron Pharma as a standalone stock will no longer find it listed on any exchange. The biopharmaceutical firm's journey as an independent public company concluded definitively when it was acquired by the industry giant Merck & Co. This integration marks the final chapter for the former entity's equity.

In a significant consolidation within the biotechnology industry, Merck & Co. announced its agreement to acquire Acceleron Pharma in September 2021. The transaction, finalized just two months later in November 2021, carried an approximate total value of $11.5 billion. Following the deal's completion, Acceleron was converted into a subsidiary, leading to the immediate cessation of its independent stock trading.

The Driving Force Behind the Premium

The substantial price Merck was willing to pay was primarily justified by Acceleron's promising pipeline, with a particular focus on cardiovascular therapies. The key asset was the drug candidate sotatercept, developed for treating pulmonary arterial hypertension (PAH). This novel therapeutic approach was seen as a pivotal asset to strengthen and diversify Merck's cardiovascular portfolio by addressing a significant unmet medical need in a growing market.

Should investors sell immediately? Or is it worth buying Acceleron Pharma?

Further enhancing the strategic value of the acquisition was Reblozyl, a therapy designed to promote red blood cell maturation. Together, these innovative pipeline assets presented a compelling rationale for the multi-billion dollar deal.

As of February 2026, the Acceleron brand has been fully absorbed into Merck's operational framework. Any contemporary discussion regarding its "stock performance" is purely historical, referring to its trajectory prior to the takeover. The development of its former pipeline assets now continues entirely within Merck's global research programs.